Akari Therapeutics Plc — Director's Dealing 2015

Jan 2, 2015

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Celsus Therapeutics Plc. (CLTX)
CIK: 0001541157
Period of Report: 2015-01-01

Reporting Person: Doman Robert F (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Options to Purchase Ordinary Shares	$2.00	2023-04-29	Ordinary Shares (70000)		Direct
Options to Purchase Ordinary Shares	$0.75	2024-02-05	Ordinary Shares (25000)		Direct
Options to Purchase Ordinary Shares	$0.60	2024-07-22	Ordinary Shares (45000)		Direct

Footnotes

F1: 1/3 of the shares underlying the options vest annually, beginning on 4/26/2014.

F2: 100% of the shares underlying the options vested on 5/31/2014.

F3: 100% of the shares underlying the options will vest on 6/1/2015.